TWI893162B - 1-[1-(4-苄氧基-3,5-二氟-苯甲醯)-4-氟-吡咯烷-2-羰基]-吡咯烷-2-腈 - Google Patents

1-[1-(4-苄氧基-3,5-二氟-苯甲醯)-4-氟-吡咯烷-2-羰基]-吡咯烷-2-腈

Info

Publication number
TWI893162B
TWI893162B TW110124773A TW110124773A TWI893162B TW I893162 B TWI893162 B TW I893162B TW 110124773 A TW110124773 A TW 110124773A TW 110124773 A TW110124773 A TW 110124773A TW I893162 B TWI893162 B TW I893162B
Authority
TW
Taiwan
Prior art keywords
compound
formula
pyrrolidine
salt
benzyloxy
Prior art date
Application number
TW110124773A
Other languages
English (en)
Chinese (zh)
Other versions
TW202216689A (zh
Inventor
克魯瓦 特蕾莎 塔拉格
科薩諾 羅杰 普拉德斯
Original Assignee
西班牙商阿庫勒療法有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 西班牙商阿庫勒療法有限公司 filed Critical 西班牙商阿庫勒療法有限公司
Publication of TW202216689A publication Critical patent/TW202216689A/zh
Application granted granted Critical
Publication of TWI893162B publication Critical patent/TWI893162B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
TW110124773A 2020-07-07 2021-07-06 1-[1-(4-苄氧基-3,5-二氟-苯甲醯)-4-氟-吡咯烷-2-羰基]-吡咯烷-2-腈 TWI893162B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPEP20382606.0 2020-07-07
EP20382606 2020-07-07

Publications (2)

Publication Number Publication Date
TW202216689A TW202216689A (zh) 2022-05-01
TWI893162B true TWI893162B (zh) 2025-08-11

Family

ID=71607883

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110124773A TWI893162B (zh) 2020-07-07 2021-07-06 1-[1-(4-苄氧基-3,5-二氟-苯甲醯)-4-氟-吡咯烷-2-羰基]-吡咯烷-2-腈

Country Status (19)

Country Link
US (1) US12459891B2 (enExample)
EP (1) EP4178945B1 (enExample)
JP (1) JP7628716B2 (enExample)
KR (1) KR20230035604A (enExample)
CN (1) CN117545738A (enExample)
AU (1) AU2021303440A1 (enExample)
BR (1) BR112023000335A2 (enExample)
CA (1) CA3185064A1 (enExample)
ES (1) ES2997164T3 (enExample)
HR (1) HRP20241527T1 (enExample)
HU (1) HUE068953T2 (enExample)
IL (1) IL299035B1 (enExample)
MA (1) MA60250B1 (enExample)
MX (1) MX2023000261A (enExample)
RS (1) RS66215B1 (enExample)
SM (1) SMT202400460T1 (enExample)
TW (1) TWI893162B (enExample)
WO (1) WO2022008477A1 (enExample)
ZA (1) ZA202213708B (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072498A1 (en) * 2012-11-12 2014-05-15 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
DE19603510A1 (de) 1996-02-01 1997-08-07 Knoell Hans Forschung Ev Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase
FI20011466A0 (fi) 2001-07-04 2001-07-04 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö
FI20030014A0 (fi) 2003-01-03 2003-01-03 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
FI20031018A0 (fi) 2003-07-04 2003-07-04 Orion Corp Parannus aivovammasta toipumiseen
WO2005027934A1 (ja) 2003-09-24 2005-03-31 Nippon Kayaku Kabushiki Kaisha プロリルオリゴペプチダーゼ阻害剤
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
ES2302473B1 (es) 2006-12-22 2009-06-12 Universidad De Barcelona Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072498A1 (en) * 2012-11-12 2014-05-15 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Also Published As

Publication number Publication date
ZA202213708B (en) 2024-04-24
IL299035A (en) 2023-02-01
JP7628716B2 (ja) 2025-02-12
SMT202400460T1 (it) 2025-01-14
EP4178945B1 (en) 2024-08-28
BR112023000335A2 (pt) 2023-01-31
US12459891B2 (en) 2025-11-04
AU2021303440A1 (en) 2023-02-02
CN117545738A (zh) 2024-02-09
EP4178945C0 (en) 2024-08-28
US20230250058A1 (en) 2023-08-10
WO2022008477A1 (en) 2022-01-13
ES2997164T3 (en) 2025-02-14
EP4178945A1 (en) 2023-05-17
CA3185064A1 (en) 2022-01-13
HUE068953T2 (hu) 2025-02-28
MX2023000261A (es) 2023-04-13
JP2023533932A (ja) 2023-08-07
MA60250B1 (fr) 2024-11-29
TW202216689A (zh) 2022-05-01
KR20230035604A (ko) 2023-03-14
HRP20241527T1 (hr) 2025-01-03
IL299035B1 (en) 2026-03-01
RS66215B1 (sr) 2024-12-31

Similar Documents

Publication Publication Date Title
US10611727B2 (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
JP5911503B2 (ja) アミロイド線維形成関連状態を処置するためのジペプチドアナログ
TWI579269B (zh) 作爲alx受體激動劑之經氟化橋聯之螺[2.4]庚烷衍生物
JP2025097980A (ja) 神経変性疾患の治療におけるペプチド模倣化合物(r)-2-アミノ-n-((s)-l-(((s)-5-アミノ-l-(3-ベンジル-1,2,4-オキサジアゾール-5-イル)ペンチル)アミノ)-3-(4-ヒドロキシ-2,6-ジメチルフェニル)-i-オキソプロパン-2-イル)-5-グアニジノペンタンアミド
US8765953B2 (en) Compounds and methods for the treatment of pain and other diseases
RU2841064C1 (ru) 1-[1-(4-бензилокси-3,5-дифтор-бензоил)-4-фтор-пирролидин-2-карбонил]-пирролидин-2-карбонитрил
EP4178945B1 (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
HK40084881B (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
HK40084881A (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
HK1214597B (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
JP2009516734A (ja) Cns状態を治療するために有用な置換アザシクロアルカン
JP2021522301A (ja) ジペプチジルケトアミドメタ−メトキシフェニル誘導体およびその使用
WO2006009325A1 (ja) メタロプロテアーゼ阻害剤
WO2008083543A1 (fr) Composés modifiés hétérocycliques contenant de l'azote et leurs utilisations